# A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.

> **NCT00676910** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 71 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** JNJ-26854165

## Key facts

- **NCT ID:** NCT00676910
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2010-02
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2010-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676910, "A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00676910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*